変異株に対する免疫応答・有効性

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
 Planas D, et al.〔Nature. 2021 Aug;596(7871):276-280〕（査読済み）


mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
 Chemaitelly H, et al.〔Nat Med. 2021 Jul 9〕（査読済み）


Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
 Charmet T, et al.〔Lancet Reg Health Eur. 2021 Sep;8:100171〕（査読済み）


Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
 Barros-Martins J, et al.〔Nat Med. 2021 Jul 14〕（査読済み）


Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications
 Montastruc JL, et al.〔Fundam Clin Pharmacol. 2021 Jul 1〕（査読済み）


Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 (Correspondence)
 Lustig Y, et al.〔N Engl J Med. 2021 Jun 24;384(25):2453-2454〕（査読済み）


BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (Correspondence)
 Liu Y, et al.〔N Engl J Med. 2021 Jul 29;385(5):472-474〕（査読済み）


Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants (Correspondence)
 Edara VV, et al.〔N Engl J Med. 2021 Aug 12;385(7):664-666〕（査読済み）


Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
 Cromer D, et al.〔Lancet Microbe. 2021 Nov 15〕（査読済み）


Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
 Grant R, et al.〔Lancet Reg Health Eur. 2021 Nov 26;100278〕（査読済み）


Covid-19 Vaccine Effectiveness in New York State
 Rosenberg E S, et al.〔N Engl J Med. 2021 Dec 1;NEJMoa2116063〕（査読済み）


Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021 (Research Letter)
 Young-Xu Y, et al.〔JAMA Netw Open. 2021 Dec 1;4(12):e2138975〕（査読済み）


Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
 Dickerman BA, et al.〔N Engl J Med. 2022 Jan 13;386(2):105-115〕（査読済み）


Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum (Correspondence)
 Dejnirattisai W, et al.〔Lancet. 2022 Jan 15;399(10321):234-236〕（査読済み）


SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons (Correspondence)
 Rössler A, et al.〔N Eng J Med. 2022 Feb 17;386(7):698-700〕（査読済み）


Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
 Accorsi EK, et al.〔JAMA. 2022 Feb 15;327(7):639-651〕（査読済み）


SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (Correspondence)
 Pajon R, et al.〔N Engl J Med. 2022 Jan 26;NEJMc2119912〕（査読済み）


Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
 Takashita E, et al.〔N Engl J Med. 2022 Mar 10;386(10):995-998〕（査読済み）


Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 (Correspondince)
 Takashita E, et al.〔N Engl J Med. 2022 Mar 9;NEJMc2201933〕（査読済み）


Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
 Wratil PR, et al.〔Nat Med. 2022 Mar;28(3):496-503〕（査読済み）


規制機関情報


Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
 〔カナダ Health Canada 〕


ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern
 〔EU EMA（European Medicines Agency）〕